Scientific Sessions 2024  /  Managing Hyperkalemia in Heart Failure: Overcoming Roadblocks with Best Practices  /  Presentation
Logo

American Heart Association

  2
  0

Final ID:

Presentation

  • Cherney, David  ( Toronto General Hospital , Toronto , Ontario , Canada )
  • Petrie, Mark  ( University of Glasgow , Glasgow , United Kingdom )
  • Zieroth, Shelley  ( Univ of Manitoba , Winnipeg , Manitoba , Canada )
  • Kosiborod, Mikhail  ( ST LUKES HEALTH SYSTEM , Kansas City , Missouri , United States )
    • Author Disclosures:
    David Cherney: DO have relevant financial relationships ; Consultant:Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk (consultant and/or speaker):Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk:Active (exists now) | Mark Petrie: DO NOT have relevant financial relationships | Shelley Zieroth: DO have relevant financial relationships ; Consultant:Novartis:Past (completed) | Mikhail Kosiborod: DO have relevant financial relationships ; Consultant:35Pharma, Imbria Pharmaceuticals:Active (exists now) ; Consultant:Esperion Therapeutics, Structure Therapeutics:Active (exists now) ; Consultant:Eli Lilly, scPharmaceuticals:Active (exists now) ; Consultant:Dexcom, Sanofi, Youngene Therapeutics:Active (exists now) ; Consultant:Cytokinetics, Regeneron:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer, Pharmacosmos:Active (exists now) ; Other (please indicate in the box next to the company name):AstraZeneca, Vifor Pharma - data analytic center fees:Active (exists now) ; Consultant:AstraZeneca, Pfizer, Vifor Pharma:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca, Pfizer:Active (exists now) ; Consultant:Arrowhead Pharmaceuticals:Active (exists now) ; Consultant:Applied Therapeutics:Active (exists now) ; Consultant:Amgen, NovoNordisk:Active (exists now) ; Consultant:Alnylam, Merck (Diabetes and Cardiovascular):Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Managing Hyperkalemia in Heart Failure: Overcoming Roadblocks with Best Practices

Sunday, 11/17/2024 , 06:00PM - 07:30PM

Satellite Symposia

More abstracts from these authors:
Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial

Kosiborod Mikhail, Cherney David, Desai Akshay, Testani Jeffrey, Verma Subodh, Dahl Magnus, Eudicone James, Friberg Lovisa, Petrie Mark

The evolving therapeutic landscape in obesity and the effect on cardiovascular outcomes

Kosiborod Mikhail

You have to be authorized to contact abstract author. Please, Login
Not Available